|
|
 |
|
Viewing report
|
|
|
|
Myelodysplastic Syndromes: Pathobiology and Clinical Management, Second Edition
Informa Healthcare, Nov 2008, Pages: 536
Written by a team of leading authorities in pathogenesis, diagnostic techniques, and clinical management strategies in myelodysplastic syndrome (MDS), this text provides a concise, easy-to-follow review of the advances in the science, classification, diagnosis, and management of the condition.
An ideal source for hematologists, oncologists, and cancer researchers, this Second Edition features:
- a new eight-page color insert
- 200 color and black-and-white illustrations
- reworked content organized into three sections: MDS epidemiology and biology; diagnosis, classification, and prognosis; and MDS therapy
- thoroughly updated chapters reflecting a shift from the topical focus as dictated by the evolution of the field
New topics in Myelodysplastic Syndrome include:
- del(5q) and 5q-syndrome, CMML, and MDS-MPD overlap syndrome
- the reborn DNA methyltransferase inhibiting nucleoside analogs
- the diagnosis of chronic myelomonocytic leukemia and other MDS cases with myeloproliferative features
- the role of mitochondria and the potential importance of iron overload in MDS
- global genomics approaches, such as cDNA expression arrays, array-based comparative genomic hybridization, and single nucleotide polymorphism array
- the role of abnormal mitochondrial ferritin accumulation and other mitochondrial metabolic anomalies in MD
- other disease-associated alterations, such as abnormalities of B lymphocyte populations in MD
- three recently approved drugs: azacitidine, lenalidomide, and decitabine
|
|
|
|
